AR009958A1 - ADJUVANT COMPOSITIONS; VACCINES FORMULATED WITH SUCH COMPOSITIONS; THE USE OF SUCH COMPOSITIONS IN THE PREPARATION OF VACCINES AND PROCEDURE FOR PREPARING SUCH VACCINES. - Google Patents

ADJUVANT COMPOSITIONS; VACCINES FORMULATED WITH SUCH COMPOSITIONS; THE USE OF SUCH COMPOSITIONS IN THE PREPARATION OF VACCINES AND PROCEDURE FOR PREPARING SUCH VACCINES.

Info

Publication number
AR009958A1
AR009958A1 ARP970104569A ARP970104569A AR009958A1 AR 009958 A1 AR009958 A1 AR 009958A1 AR P970104569 A ARP970104569 A AR P970104569A AR P970104569 A ARP970104569 A AR P970104569A AR 009958 A1 AR009958 A1 AR 009958A1
Authority
AR
Argentina
Prior art keywords
vaccines
compositions
preparation
formulated
preparing
Prior art date
Application number
ARP970104569A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR009958A1 publication Critical patent/AR009958A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se trata de composiciones adyuvantes, formuladas con alumbre, fracciones de saponinas inmunologicamente activas, y un esterol, particularmente colesterol.De preferencia, se trata de saponinas provenientes de la corteza de Quillaja SaponariaMolin a, tal como la fraccion Q21. También se proponen vacunas queincluyen dichas composiciones adyuvantes, para el tratamiento de enfermos de cancer o el tratamiento profilactico de infecciones. También se reivindica lapreparacion de dichasvacunas y l a preparacion de las composiciones adyuvantes mencionadas.These are adjuvant compositions, formulated with alum, immunologically active saponin fractions, and a sterol, particularly cholesterol. Preferably, they are saponins from the bark of Quillaja SaponariaMolin a, such as fraction Q21. Vaccines including such adjuvant compositions are also proposed, for the treatment of cancer patients or the prophylactic treatment of infections. The preparation of said vaccines and the preparation of the mentioned adjuvant compositions are also claimed.

ARP970104569A 1996-10-05 1997-10-03 ADJUVANT COMPOSITIONS; VACCINES FORMULATED WITH SUCH COMPOSITIONS; THE USE OF SUCH COMPOSITIONS IN THE PREPARATION OF VACCINES AND PROCEDURE FOR PREPARING SUCH VACCINES. AR009958A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9620795.6A GB9620795D0 (en) 1996-10-05 1996-10-05 Vaccines

Publications (1)

Publication Number Publication Date
AR009958A1 true AR009958A1 (en) 2000-05-17

Family

ID=10800990

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104569A AR009958A1 (en) 1996-10-05 1997-10-03 ADJUVANT COMPOSITIONS; VACCINES FORMULATED WITH SUCH COMPOSITIONS; THE USE OF SUCH COMPOSITIONS IN THE PREPARATION OF VACCINES AND PROCEDURE FOR PREPARING SUCH VACCINES.

Country Status (19)

Country Link
EP (1) EP0939650A1 (en)
JP (1) JP2001501640A (en)
KR (1) KR20000048866A (en)
CN (1) CN1238696A (en)
AR (1) AR009958A1 (en)
AU (1) AU714930B2 (en)
BR (1) BR9711853A (en)
CA (1) CA2267191A1 (en)
CO (1) CO4910170A1 (en)
CZ (1) CZ116799A3 (en)
GB (1) GB9620795D0 (en)
HU (1) HUP9904549A3 (en)
IL (1) IL128985A0 (en)
NO (1) NO991524D0 (en)
NZ (1) NZ334734A (en)
PL (1) PL332633A1 (en)
TR (1) TR199900729T2 (en)
WO (1) WO1998015287A1 (en)
ZA (1) ZA978868B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654522C (en) * 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1588714A2 (en) * 1998-10-16 2005-10-26 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ303515B6 (en) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvant compositions
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ATE291008T1 (en) 1999-09-24 2005-04-15 Nihon Nohyaku Co Ltd AROMATIC DIAMIDE DERIVATIVES OR SALTS THEIR, AGRICULTURAL/HORTICULTURE CHEMICALS AND METHOD FOR USE THEREOF
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
EP1235591A1 (en) * 1999-12-08 2002-09-04 Statens Veterinärmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
ATE346925T1 (en) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd IMMUNOGENIC POLYPEPTIDES ENCODED BY MAGE MINIGENE AND USES THEREOF
ES2392943T3 (en) 2000-10-18 2012-12-17 Glaxosmithkline Biologicals S.A. Anti-tumor vaccines
WO2002074336A2 (en) * 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
US20040096463A1 (en) * 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
JP2006504687A (en) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Method for isolating hepatitis C virus peptide
ES2594758T3 (en) 2002-10-23 2016-12-22 Glaxosmithkline Biologicals S.A. Vaccination procedures against malaria
WO2004084937A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
ATE485056T1 (en) 2003-03-24 2010-11-15 Intercell Ag IMPROVED VACCINES
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514838A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Adjuvant vaccine containing non-virion antigen prepared from influenza virus grown in cell culture
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
TW201350129A (en) 2005-12-22 2013-12-16 Glaxosmithkline Biolog Sa Streptococcus pneumoniae immunogenic composition comprising capsular saccharide conjugates, vaccine and kit comprising the same and uses thereof
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2647441C (en) 2006-03-30 2021-02-23 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising staphylococcus aureus saccharides
US9364525B2 (en) 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
AU2007322424B2 (en) * 2006-11-20 2013-05-16 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
CA2896131C (en) 2007-03-02 2020-04-07 Glaxosmithkline Biologicals S.A. Novel method and compositions
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
UY31285A1 (en) 2007-08-13 2009-03-31 VACCINES
US10040825B2 (en) 2007-12-19 2018-08-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
ES2608841T3 (en) 2009-02-10 2017-04-17 Seqirus UK Limited Flu shots with reduced amounts of squalene
AU2010220824A1 (en) * 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011117408A1 (en) 2010-03-26 2011-09-29 Glaxosmithkline Biologicals S.A. Hiv vaccine
US20130259948A1 (en) 2010-09-21 2013-10-03 National Institute Of Immunology Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
BR112013004582A2 (en) 2010-09-27 2016-09-06 Crucell Holland Bv method for inducing an immune response in a subject against a parasite antigen that causes malaria
SI2758432T1 (en) 2011-09-16 2019-07-31 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
BR112019003462A2 (en) 2016-08-23 2019-06-25 Glaxosmithkline Biologicals Sa fusion protein, polynucleotide, viral vector, pharmaceutical composition, use of a fusion protein, polynucleotide, viral vector or pharmaceutical composition, and method for treating or preventing viral hepatitis b infection or viral hepatitis c infection
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BE1024774B1 (en) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa COMPOSITIONS AND METHODS OF TREATMENT
BE1025160B1 (en) * 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa NEW PROCESS
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
BR112019025193A2 (en) * 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. METHODS OF MANUFACTURING A LIPOSOMAL ADJUVANT, MANUFACTURING A LIPOSOMAL CONCENTRATE, FOR THE PREPARATION OF AN IMMUNOGENIC COMPOSITION WITH ADJUVANT AND FOR THE PREPARATION OF A SOLUTION, LIPOSOMAL ADJUVANT, IMMUNOGENOUS COMPOUND, WITH SOLUTION,
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
US11702674B2 (en) 2018-06-12 2023-07-18 Glaxosmithkline Biologicals Sa Simian adenovirus vectors comprising the ChAd-157 fiber protein
BR112021000965A2 (en) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processes and vaccines
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CN113573730A (en) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 Hepatitis B immunization protocols and compositions
WO2023056117A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic combination of alum and non-liposome, non-micelle particle vaccine adjuvants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
IL102639A (en) * 1991-07-25 1997-03-18 Idec Pharma Corp Compositions for inducing cytotoxic t lymphocyte responses
DE69432665T3 (en) * 1993-03-29 2007-12-06 Pfizer Inc. MULTICOMPONENT VACCINE FROM CLOSTRIDIA USING SAPONINE AS ADJUVANS
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine

Also Published As

Publication number Publication date
CN1238696A (en) 1999-12-15
PL332633A1 (en) 1999-09-27
WO1998015287A1 (en) 1998-04-16
HU9904549A (en) 2000-05-28
JP2001501640A (en) 2001-02-06
GB9620795D0 (en) 1996-11-20
AU714930B2 (en) 2000-01-13
ZA978868B (en) 1999-04-06
EP0939650A1 (en) 1999-09-08
BR9711853A (en) 1999-08-24
AU4781297A (en) 1998-05-05
CO4910170A1 (en) 2000-04-24
TR199900729T2 (en) 1999-07-21
NZ334734A (en) 2000-05-26
NO991524L (en) 1999-03-29
KR20000048866A (en) 2000-07-25
CA2267191A1 (en) 1998-04-16
HUP9904549A3 (en) 2001-06-28
CZ116799A3 (en) 1999-08-11
NO991524D0 (en) 1999-03-29
IL128985A0 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
AR009958A1 (en) ADJUVANT COMPOSITIONS; VACCINES FORMULATED WITH SUCH COMPOSITIONS; THE USE OF SUCH COMPOSITIONS IN THE PREPARATION OF VACCINES AND PROCEDURE FOR PREPARING SUCH VACCINES.
EA201001189A1 (en) VACCINE COMPOSITIONS CONTAINING SAPONIN ADJUVANT
NO20005051L (en) Adjuvantsammensetninger
BR0312472A (en) Preparation of a composition comprising a mixture of iscom complexes and use of said composition
AR001686A1 (en) A composition vaccinates a process for preparing it and its use for the manufacture of a vaccine
FI971498A0 (en) Saponin preparations and their use in isomers
ATE116993T1 (en) SAPONIN REMEDIES.
UA40597C2 (en) Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
AU2002338832A1 (en) Vaccine
AR008799A1 (en) VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
ATE179614T1 (en) HERPES SIMPLEX VIRUS VP16 VACCINES
DK0482097T3 (en) Surfactant preparations and methods
PT792165E (en) IMMUNOGENIC COMPOSITIONS
AU2821200A (en) Matrix protein compositions for grafting
AR023536A1 (en) VACCINES
WO2002038168A3 (en) Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases
BR0212834A (en) Formulations and use thereof
YU37402A (en) Vaccine for healing prostate inflammation and benign prostate hyperplasia, that includes lactobacillus layers
ATE155041T1 (en) RECTAL PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PROSTATE SWELLING
BR0016092A (en) Compound, use of a compound kit for hormonal contraception in a male, and method of treatment

Legal Events

Date Code Title Description
FB Suspension of granting procedure